the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
December 29, 2023 – Alzheimer’s disease is a neurodegenerative human disease that occurs in its most common form in people over the age of 65 and is characterized by increasing dementia. It is responsible for approximately 60 percent of the …
Alzheimer’s: Are we at the beginning of a new era of treatment? Read more »
13 June 2022 – Sometimes, patients genetics can be bewildering and/or unjust. Common belief with patients and the general public would be that genetic variants would be responsible for causing all kinds of adverse drug reactions (ADR’s) and be at the …
Rare APOE genetic variants reduce Alzheimer’s risk Read more »
September 09. 2016 – The pre-clinical animal model and Phase 1b placebo-controlled study in prodromal and mild Alzheimer Disease (AD) patients (n=165), both demonstrate that aducanumab reduced amyloid-beta in the brain and the reduction was dose-dependent. Amyloid-beta plaque is associated …
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Read more »